{
    "clinical_study": {
        "@rank": "153319", 
        "arm_group": {
            "arm_group_label": "Treatment (ipilimumab)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over 90 minutes on day 1. Courses repeat every 2 months in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial is studying the side effects of monoclonal antibody therapy in treating\n      patients with ovarian epithelial cancer, melanoma, acute myeloid leukemia, myelodysplastic\n      syndrome, or non-small cell lung cancer. Monoclonal antibodies can locate tumor cells and\n      either kill them or deliver tumor-killing substances to them without harming normal cells"
        }, 
        "brief_title": "Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer", 
        "condition": [
            "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", 
            "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", 
            "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", 
            "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", 
            "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", 
            "Previously Treated Myelodysplastic Syndromes", 
            "Recurrent Adult Acute Myeloid Leukemia", 
            "Recurrent Melanoma", 
            "Recurrent Non-small Cell Lung Cancer", 
            "Recurrent Ovarian Epithelial Cancer", 
            "Stage IV Melanoma", 
            "Stage IV Non-small Cell Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Neoplasms", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Lung Neoplasms", 
                "Melanoma", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Myeloproliferative Disorders", 
                "Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative", 
                "Neoplasms, Glandular and Epithelial", 
                "Ovarian Neoplasms", 
                "Myelodysplastic-Myeloproliferative Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the safety of MDX-CTLA-4 in patients previously and not previously\n      vaccinated with GM-CSF-based vaccines using lethally irradiated, autologous melanoma,\n      ovarian cancer, acute myelogenous leukemia/myelodysplasia or lung cancer cells.\n\n      II. To identify preliminary evidence of biologic activity and efficacy.\n\n      OUTLINE:\n\n      Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV\n      over 90 minutes on day 1. Courses repeat every 2 months in the absence of disease\n      progression or unacceptable toxicity.\n\n      Patients are followed monthly until disease progression.\n\n      PROJECTED ACCRUAL: A total of 48 patients (12 per disease type; 36 previously treated with a\n      sargramostim (GM-CSF)-expressing autologous tumor cell vaccine and 12 not previously treated\n      with this vaccine) will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients previously vaccinated with GM-CSF-based vaccines using lethally irradiated,\n             autologous melanoma, ovarian cancer, acute myelogenous leukemia/myelodysplasia, or\n             non-small cell lung cancer cells; patients with acute myelogenous\n             leukemia/myelodysplasia or non-small cell lung cancer who have not been vaccinated\n             with an autologous, GM-CSF based vaccine\n\n          -  >= 4 weeks since treatment (chemo-, radiation, hormone, immuno-, etc., therapy)\n\n          -  Patients must have recovered from any acute toxicity associated with prior therapy\n\n          -  Measurable epithelial ovarian cancer, melanoma, AML/MDS, or non-small cell lung\n             cancer\n\n          -  No standard curative treatment options\n\n          -  Not require immediate palliative therapy\n\n          -  Patients with epithelial ovarian cancer must have persistent or recurrent disease\n             following primary surgery and primary chemotherapy\n\n          -  Patients with melanoma must be stage IV disease\n\n          -  Patients with AML/MDS, but without MDS, must be: a) in second relapse or b) first\n             relapse with no option for bone marrow transplant or c) not a candidate for\n             immunosuppressive chemotherapy due to age or comorbid disease\n\n          -  Patients with non-small cell lung cancer must be not curable by standard surgery,\n             chemotherapy, and/or radiation\n\n          -  Life expectancy >= 12 weeks\n\n          -  ECOG performance status of 0, 1 or 2\n\n          -  Written informed consent\n\n          -  Due to the unknown effects of MDX-CTLA-4 on the fetus or nursing infant, pregnant or\n             nursing women should not be included; women should be either: post-menopausal for at\n             least 1 year; surgically incapable of bearing children; or utilizing an intrauterine\n             device, and/or spermicide and barrier, for contraception; during the study, use of\n             oral contraception alone is not acceptable; women of childbearing potential must have\n             a negative serum beta-HCG pregnancy test conducted during screening, and a negative\n             urinary beta-HCG pregnancy test conducted within 24 hours prior to treatment; due to\n             the unknown effects of MDX-CTLA-4 on the fetus, men should not father children during\n             the study\n\n          -  WBC > 1,000 cells/mm^3 (except for AML/MDS patients)\n\n          -  Serum creatinine < 2 mg/dL\n\n          -  Platelets > 75,000 cells/mm^3 (except for AML/MDS patients)\n\n          -  AST and ALT < 2 x UNL\n\n          -  Total bilirubin < 2 x UNL\n\n        Exclusion Criteria:\n\n          -  Active infection\n\n          -  Autoimmune disease requiring immunosuppressive treatment\n\n          -  Any underlying medical condition which, in the principal investigator's opinion, will\n             make the administration of study drug hazardous or obscure the interpretation of\n             adverse events\n\n          -  Any concurrent medical condition requiring the use of systemic steroids (use of\n             inhaled or topical steroids is acceptable)\n\n          -  CNS metastases, unless previously treated and stable for at least three months\n\n          -  Patients who have received prior treatment with MDX-CTLA-4"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 6, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00039091", 
            "org_study_id": "NCI-2012-03144", 
            "secondary_id": [
                "01-228", 
                "R21CA105776", 
                "CDR0000069349"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Treatment (ipilimumab)", 
            "description": "Given IV", 
            "intervention_name": "ipilimumab", 
            "intervention_type": "Biological", 
            "other_name": [
                "anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody", 
                "MDX-010", 
                "MDX-CTLA-4", 
                "monoclonal antibody CTLA-4"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal", 
                "Cytotoxic T-lymphocyte antigen 4"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02115"
                }, 
                "name": "Dana-Farber Cancer Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 (Anti-CTLA-4) Humanized Monoclonal Antibody (MDX-CTLA-4 NSC# 732442, Previously 720801) in Patients Previously Vaccinated With GM-CSF-Based Autologous Tumor Vaccines (CTEP Protocol Number P-5708) and Patients With Acute Myelogenous Leukemia/ Myelodysplasia, and Non-Small Cell Lung Cancer Who Have Not Received a Prior Vaccine", 
        "overall_official": {
            "affiliation": "Dana-Farber Cancer Institute", 
            "last_name": "Frank Hodi", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Toxicities of ipilimumab, based on the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 6 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00039091"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "90% confidence intervals will be estimated.", 
                "measure": "Overall clinical response rate (complete response [CR] plus partial response [PR]) based on the Response Evaluation Criteria in Solid Tumors (RECIST)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 years"
            }, 
            {
                "description": "90% confidence intervals will be estimated.", 
                "measure": "Proportion of patients who mount a brisk immune response, graded as absent, non-brisk, and brisk as described by Mihm", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 months post-treatment"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }, 
    "geocoordinates": {
        "Dana-Farber Cancer Institute": "42.358 -71.06"
    }
}